Controls
7
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
QUANTIFY: Quantitative Understanding of Advanced Novel Techniques for Imaging Fasciitis and Yielding Biomarkers
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Test-retest Reliability and Agreement of Trunk Muscle Activation in Pain-free Persons
Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms
A Mobile App to Improve Participation in Following-up Cohorts
Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness
Traumatic Brain Injury Feasibility Study (EPIC-011)